Raymond James & Associates’s Trillium Therapeutics Inc. TRIL Stock Holding History

Raymond James & Associates’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-42,037	Closed	-$738K	–	4373
2021 Q3	$738K	Buy	42,037 +6,131	+17%	+$71.6K	﹤0.01%	2777
2021 Q2	$348K	Buy	35,906 +1,424	+4%	+$13.4K	﹤0.01%	3330
2021 Q1	$370K	Buy	34,482 +20,885	+154%	+$258K	﹤0.01%	3226
2020 Q4	$200K	Buy	+13,597	New	+$196K	﹤0.01%	3403

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Raymond James & Associates's TRIL Position: Q4 2021 in Review

Raymond James & Associates sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 42,037 shares — an estimated $738K sold.

Raymond James & Associates first reported a position in TRIL in Q4 2020 and held it in 4 quarters. The position peaked at $738K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Raymond James & Associates reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Raymond James & Associates sold 42,037 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $738K.
Raymond James & Associates first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 4 quarters.
Raymond James & Associates's Trillium Therapeutics Inc. position peaked at $738K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.